All In Biotech

Drug Trial Radar · NCT05143528

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease

A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Last checked: Nov 19, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,275 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,275

Planned (sponsor's estimate)

Start

Feb 1, 2022

Primary completion

Dec 31, 2025

Study completion Jun 1, 2026

Sponsor

Lead sponsor
KeifeRx, LLCIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceutical Industries Limited
First posted
Dec 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will investigate the safety and efficacy of a Tyrosine Kinase Inhibitor (TKI) called Nilotinib BE (bioequivalent) in individuals with Early Alzheimer's disease (EAD). This is a multi-center double blinded, Phase 3 study, that will enroll patients for three years in approximately 50 centers nationwide. The total duration of the study will be for five years.

Conditions

  • Alzheimer Disease

Interventions

  • Nilotinib BE 84mgDrug

    84 mg capsule

  • Nilotinib BE 112 mgDrug

    112 mg capsule

  • PlaceboDrug

    placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 72 [ Time Frame: Baseline, Week 72]Time frame: 72 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.